Background: The effectiveness of influenza vaccine during 2015-2016 was reduced in some age groups as compared to that in previous 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09 virus)-predominant seasons. We hypothesized that the age at first exposure to specific influenza A(H1N1) viruses could influence vaccine effectiveness (VE). Methods: We estimated the effectiveness of influenza vaccine against polymerase chain reaction-confirmed influenza A(H1N1)pdm09-associated medically attended illness from the 2010-2011 season through the 2015-2016 season, according to patient birth cohort using data from the Influenza Vaccine Effectiveness Network. Birth cohorts were defined a priori on the basis of likely immunologic priming with groups of influenza A(H1N1) viruses that circulated during 1918-2015. VE was calculated as 100 × [1 - adjusted odds ratio] from logistic regression models comparing the odds of vaccination among influenza virus-positive versus influenza test-negative patients. Results: A total of 2115 A(H1N1)pdm09 virus-positive and 14 696 influenza virus-negative patients aged ≥6 months were included. VE was 61% (95% confidence interval [CI], 56%-66%) against A(H1N1)pdm09-associated illness during the 2010-2011 through 2013-2014 seasons, compared with 47% (95% CI, 36%-56%) during 2015-2016. During 2015-2016, A(H1N1)pdm09-specific VE was 22% (95% CI, -7%-43%) among adults born during 1958-1979 versus 61% (95% CI, 54%-66%) for all other birth cohorts combined. Conclusion: Findings suggest an association between reduced VE against influenza A(H1N1)pdm09-related illness during 2015-2016 and early exposure to specific influenza A(H1N1) viruses.
Background: The effectiveness of influenza vaccine during 2015-2016 was reduced in some age groups as compared to that in previous 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09 virus)-predominant seasons. We hypothesized that the age at first exposure to specific influenza A(H1N1) viruses could influence vaccine effectiveness (VE). Methods: We estimated the effectiveness of influenza vaccine against polymerase chain reaction-confirmed influenza A(H1N1)pdm09-associated medically attended illness from the 2010-2011 season through the 2015-2016 season, according to patient birth cohort using data from the Influenza Vaccine Effectiveness Network. Birth cohorts were defined a priori on the basis of likely immunologic priming with groups of influenza A(H1N1) viruses that circulated during 1918-2015. VE was calculated as 100 × [1 - adjusted odds ratio] from logistic regression models comparing the odds of vaccination among influenza virus-positive versus influenza test-negative patients. Results: A total of 2115 A(H1N1)pdm09 virus-positive and 14 696 influenza virus-negative patients aged ≥6 months were included. VE was 61% (95% confidence interval [CI], 56%-66%) against A(H1N1)pdm09-associated illness during the 2010-2011 through 2013-2014 seasons, compared with 47% (95% CI, 36%-56%) during 2015-2016. During 2015-2016, A(H1N1)pdm09-specific VE was 22% (95% CI, -7%-43%) among adults born during 1958-1979 versus 61% (95% CI, 54%-66%) for all other birth cohorts combined. Conclusion: Findings suggest an association between reduced VE against influenza A(H1N1)pdm09-related illness during 2015-2016 and early exposure to specific influenza A(H1N1) viruses.
Authors: R Bodewes; G de Mutsert; F R M van der Klis; M Ventresca; S Wilks; D J Smith; M Koopmans; R A M Fouchier; A D M E Osterhaus; G F Rimmelzwaan Journal: Clin Vaccine Immunol Date: 2011-01-05
Authors: Michael L Jackson; Jessie R Chung; Lisa A Jackson; C Hallie Phillips; Joyce Benoit; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard Zimmerman; Mary P Nowalk; Alicia M Fry; Brendan Flannery Journal: N Engl J Med Date: 2017-08-10 Impact factor: 91.245
Authors: Martha I Nelson; Cécile Viboud; Lone Simonsen; Ryan T Bennett; Sara B Griesemer; Kirsten St George; Jill Taylor; David J Spiro; Naomi A Sengamalay; Elodie Ghedin; Jeffery K Taubenberger; Edward C Holmes Journal: PLoS Pathog Date: 2008-02-29 Impact factor: 6.823
Authors: Joshua G Petrie; Kaela Parkhouse; Suzanne E Ohmit; Ryan E Malosh; Arnold S Monto; Scott E Hensley Journal: J Infect Dis Date: 2016-10-07 Impact factor: 7.759
Authors: Richard Pebody; Fiona Warburton; Joanna Ellis; Nick Andrews; Alison Potts; Simon Cottrell; Jillian Johnston; Arlene Reynolds; Rory Gunson; Catherine Thompson; Monica Galiano; Chris Robertson; Rachel Byford; Naomh Gallagher; Mary Sinnathamby; Ivelina Yonova; Sameera Pathirannehelage; Matthew Donati; Catherine Moore; Simon de Lusignan; Jim McMenamin; Maria Zambon Journal: Euro Surveill Date: 2016-09-22
Authors: Feng Liu; F Liaini Gross; Stacie N Jefferson; Crystal Holiday; Yaohui Bai; Li Wang; Bin Zhou; Min Z Levine Journal: J Clin Invest Date: 2021-04-15 Impact factor: 14.808
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Feng Liu; Wen-Pin Tzeng; Lauren Horner; Ram P Kamal; Heather R Tatum; Elisabeth G Blanchard; Xiyan Xu; Ian York; Terrence M Tumpey; Jacqueline M Katz; Xiuhua Lu; Min Z Levine Journal: J Infect Dis Date: 2018-10-05 Impact factor: 5.226
Authors: Maria Auladell; Xiaoxiao Jia; Luca Hensen; Brendon Chua; Annette Fox; Thi H O Nguyen; Peter C Doherty; Katherine Kedzierska Journal: Front Immunol Date: 2019-07-02 Impact factor: 7.561
Authors: Michael Hinojosa; Samuel S Shepard; Jessie R Chung; Jennifer P King; Huong Q McLean; Brendan Flannery; Edward A Belongia; Min Z Levine Journal: J Infect Dis Date: 2021-08-02 Impact factor: 5.226
Authors: Eric P Griggs; Brendan Flannery; Ivo M Foppa; Manjusha Gaglani; Kempapura Murthy; Michael L Jackson; Lisa A Jackson; Edward A Belongia; Huong Q McLean; Emily T Martin; Arnold S Monto; Richard K Zimmerman; Goundappa K Balasubramani; Jessie R Chung; Manish Patel Journal: Am J Epidemiol Date: 2022-02-19 Impact factor: 5.363